Latest news with #Antiguan
New York Times
16-07-2025
- Sport
- New York Times
West Indies' cricketing decline feels terminal – and that should worry everyone
The sight of Jofra Archer, all effortless pace and menace, returning to Test cricket after a four-year injury absence in England's tense and thrilling victory over India at Lord's was an exciting one for everyone who cares about the health of the ultimate form of the game. Here was a fast bowler capable of one of cricket's most difficult and eye-catching skills — consistently bowling faster than 90 miles per hour — in full flight and playing a leading role in a classic Test that saw England go 2-1 up in their five-match series. Yet the spectacular return of the Barbados-born Archer was also bittersweet for cricket lovers in a region with one of the richest cricketing heritages of all. On the same day that Archer was lighting up Lord's, the West Indies team he could so easily have been representing crashed to arguably their lowest point in modern history. Australia had set a target of 204 — tricky, but achievable, as West Indies sought to claim a morale-boosting consolation victory. Already 2-0 down in their three-Test series, West Indies were demolished for just 27, the second-lowest total in Test history after New Zealand's 26 against England 70 years ago. Incredibly, it could have been worse. At one point West Indies were 11-6 — yes, six wickets down for just 11 runs — and staring at even greater ignominy. West Indies' decline from the greatest force in the game — back-to-back one-day World Cup champions in 1975 and 1979, and undefeated in Test series between 1980 and 1995 — to sad also-rans has been a long time coming. Yet the events at Jamaica's Sabina Park, scene of so many of West Indies great moments in a very different age, was a new nadir, and one that caused shock and embarrassment across the Caribbean. 'It's heartbreaking,' said West Indies captain Roston Chase. 'We thought we were in a position to win the game but then we had that poor batting display. It's something that has been recurring for the whole series and that makes it even more disappointing.' 'Disappointing' is probably not the word Sir Viv Richards would choose to describe it. Richards, one of the greatest of all West Indies cricketers and a man now summoned to an emergency meeting to try to sort out this mess, would likely choose a much stronger one than that. Richards was the epitome of West Indian pride in both cricket and regional identity at the height of the glory years when West Indies ruled the cricket world. Their success was largely based around having a battery of fearsome fast bowlers — all as good, if not better, than Archer — but they had brilliant batters, too, and none more so than Richards, who became one of the greatest of them all. Now the Antiguan is one of three legends of the Caribbean asked by Cricket West Indies to review the events of the last few weeks (although in reality it should probably be the last few decades) along with the captain whose strategy shaped that era of dominance, Clive Lloyd, and the holder of the world record for the highest individual scores in Test and first-class cricket, Brian Lara. Dr Kishore Shallow, president of West Indies Cricket, talked in the wake of Monday's humiliation of having 'sleepless nights' but called for patience as a committee for cricket strategy and officiating that also includes great ex-players such as Desmond Haynes and Shivnarine Chanderpaul looks for answers and starts 'rebuilding and investing in the next generation'. Investment is key, because West Indies' sad decline is all about money. The unequal sharing of the game's revenue that saw West Indies report profits of $88.4million (£66m) for 2023-24 compared to superpower India's $1.18bn demonstrates why so many of their best players now seek their employment in franchise leagues around the world as opposed to representing West Indies. In June, Nicholas Pooran, the West Indies' highest-ranked one-day batter and one of the finest Twenty20 players in the world, announced his international retirement at the age of 29. It left many in shock but it shouldn't have done: it simply continued a trend of players opting to pursue lucrative contracts in domestic cricket. West Indies are not alone in facing that challenge — South Africa have also seen players in their prime such as Heinrich Klaasen turn away from the international game — but, as their head coach Daren Sammy observed, they feel it acutely. 'More will follow in that mood, in that direction,' Sammy said. 'That's the way T20 cricket is now, and especially coming from the West Indies, with the challenges that we face trying to keep our players motivated to play for the crest, so I wouldn't be surprised.' Money also explains why West Indians, including Archer, who has an English father and a British passport and chose to play for England rather than the region of his birth, and the England prospect Jacob Bethell, also Barbadian through and through, have turned their backs on the region that once was the envy of the cricketing world. Unless the sport's governing body, the International Cricket Council, devises a fairer programme of revenue sharing — that admittedly is largely generated by India and the other big powers in England and Australia — then it is difficult to see what Richards and his fellow legends can say or do to halt what seems a terminal fall. The crash to 27 all out in Jamaica might come to be seen as the beginning of the end for West Indies cricket. But if it is, the sport will be much, much poorer for it. Click here to read more cricket stories on The Athletic, and follow Global Sports on The Athletic app via the Discover tab.
Boston Globe
16-07-2025
- Entertainment
- Boston Globe
It is a truth universally acknowledged that this year marks Jane Austen's 250th birthday
Advertisement Jane Austen, letter to her sister, Cassandra, 1808. The Morgan Library & Museum/The Morgan Library & Museum, MA 'A Lively Mind' is a show of considerable charm and no less considerable substance. It's like its subject that way. The Morgan has a special place in the world of Austeniana. It owns nearly a third of her surviving letters, the largest collection extant. Fifteen of those letters are in the show. In the most delightful one, she writes to her niece with every word spelled backward. Imagine doing that in an email; good luck with trying to get around spell check. There are almost 140 other items. They include silhouette portraits of Austen's parents and several portraits of her. None of those, alas, was drawn from life. (The only one that is, Advertisement Jane Austen, "Opinions of Emma," circa 1816. Images British Library archive/Bridgeman Images Part of what makes Austen's novels so satisfying is the fullness of the world she presents. There's a comparable fullness here: of a life led in literature, of course, but also actual life. It's hard to get more actual than a lock of Austen's hair or a gold-and-turquoise ring that belonged to her. Wallpaper from two rooms in the Austen family home, in Chawton, have been reproduced for the show: Amy Sherald, "A Single Man in Possession of a Good Fortune," 2019 © Amy Sherald. Courtesy of the artist and Hauser & Wirth. Photo: Joseph Hyde It is a truth universally acknowledged that the most famous words Austen wrote are the opening sentence of 'Pride and Prejudice': 'It is a truth universally acknowledged, that a single man in possession of a good fortune, must be in want of a wife.' In a nifty bit of updating, 'A Lively Mind' concludes with an Advertisement Henry Herschel Hay Cameron, "Mrs. Julia Margaret Cameron," 1870. © The Royal Photographic Society Collection at the V&A/© Victoria and Albert Museum, L Julia Margaret Cameron was born in what is now Kolkata, in 1815, two years before Austen's death. Austen's Bath and Southampton and Chawton were very far away, and geography is the least of it. Lest we forget, though, an Antiguan sugar plantation is the source of Sir Thomas Bertram's wealth in Austen's 'Mansfield Park.' Julia Margaret Cameron, "The Mountain Nymph Sweet Liberty," 1866. © The Royal Photographic Society Collection at the V&A In 1848, Cameron, her husband, and their children moved to England. She was 48 when she got her first camera. Over the next 11 years she would become one of the foremost photographers of the 19th century. 'Arresting Beauty: Julia Margaret Cameron' takes its title from her saying of her new-found art, 'I longed to arrest all beauty that came before me, and at length the longing has been satisfied.' Organized by London's Victoria & Albert Museum, the show runs at the Morgan through Sept. 14. It includes 80 photographs, usefully organized by theme; three pages from a brief autobiographical manuscript (a QR code lets viewers call up on their phone the remaining 18 pages); and a mighty object befitting the Victorian confidence evident in Cameron's images: her first camera lens, a gift from her husband. Julia Margaret Cameron, "The Whisper of the Muse," 1865. © The Royal Photographic Society Collection at the V&A An unusual, sometimes bewildering tension defines the work. There's the ravishing specificity of this still-new medium, photography. So many of the faces in Cameron's images have an immediacy that can make them seem almost like our contemporaries. Consider the way the young woman in 'The Mountain Nymph Sweet Liberty' stares at the viewer. The there and then of that moment when Cameron photographed her becomes our here and our now. Yet consider how earnestly bogus the title is. That title is indicative of Cameron's general fondness for staged tableaux and how she took inspiration from Renaissance painting and literature, including Shakespeare, the Bible, Browning, and Tennyson. 'Fancy Subjects for Pictorial Effect' she once called such photographs. She was being more candid than she perhaps realized. Advertisement Julia Margaret Cameron, "Julia Jackson," 1867. © The Royal Photographic Society Collection at the V&A/© Victoria and Albert Museum, L Tennyson was a neighbor. He was among the cultural luminaries Cameron photographed. The man posed in the middle of one of those fancy subjects, 'The Whisper of the Muse,' is the painter G.F. Watts. Charles Darwin said of the portrait Cameron took of him: ''I like this photograph very much better than any other which has been taken of me.' As Henry Wadsworth Longfellow was about to sit for her, Tennyson warned, 'you will have to do whatever she tells you. I will come back soon and see what is left of you.' The most striking instance of how Cameron's work could both be of its time and look ahead was also literary, if not in any way she could have intended. It's a portrait of her niece Julia Jackson. If Jackson's beauty looks so familiar it's because of how much the older of her two daughters, Virginia Woolf, resembles her. Last year was the centenary of the Morgan's becoming a public institution. In observance of the anniversary, various gifts were made to the collection. 'A Celebration: Acquisitions in Honor of the Morgan's Centennial,' a ponderously straightforward name for a wholly engaging show, consists of a selection of those items. John Coltrane, fragments and drafts for incomplete compositions, circa 1945-55. © Jowcol Music, LLC. Used By Permission/All Rights Reserved. Photography by Janny Chiu Among the 110 works — drawings, photographs, prints, manuscripts, books, and book bindings — many are associated with names that would have been familiar to the banker J.P. Morgan, who founded the library, and his namesake son, who expanded it: Leonardo, Parmigianino, Watteau. There are also names that definitely would not have been: John Coltrane, Jasper Johns, Rosamond Purcell (the first member of Somerville's Brickbottom Artists Association to enter the Morgan collection?), and the late John O'Reilly, from Worcester. Advertisement You can well imagine the first group of names moving the Morgans to reach for a checkbook. That that's in no way true of the second group speaks to how the institution has grown and evolved over the last century. Rich as 'A Celebration' is, and it is very rich, its range attests even more to what makes the Morgan so worth celebrating. A LIVELY MIND: JANE AUSTEN AT 250 ARRESTING BEAUTY: JULIA MARGARET CAMERON A CELEBRATION: Acquisitions in Honor of the Morgan's Centennial At Morgan Library & Museum, 225 Madison Ave., New York, through Sept. 14 (Austen and Cameron) and Aug. 17. 212-685-0008, Mark Feeney can be reached at
Business Wire
11-07-2025
- Business
- Business Wire
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ('SINOVAC' or the 'Company') today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the 'Special Meeting'): The Special Meeting was validly adjourned by SINOVAC Chairman Chiang Li on July 8, 2025, due to pending litigation in Antigua regarding the validity of the shares purportedly issued following an invalid private investment in public equity ('PIPE') to Advantech/Prime and Vivo Capital (together known as the 'Dissenting Investor Group'). The adjournment has been recognized by the independent Inspector of Elections who has the sole authority to announce and certify the results of the Special Meeting. SAIF's false claim that a 'continuation of the Special Meeting' occurred is intentionally deceptive and entirely illegal under the Company's bylaws and Antiguan law. Immediately after the Special Meeting was validly adjourned and the virtual meeting was terminated, a group of lawyers representing SAIF and the Dissenting Investor Group purportedly self-organized an invalid, pretend special meeting at an unannounced location and time. This group did not give advance notice to valid shareholders or give them an option to attend, and they did not contact SINOVAC Chairman Chiang Li, the only authorized chair for the Special Meeting. No inspector of elections presided over the pretend special meeting. The current SINOVAC Board understands Mr. Yuk Lam Lo attended the invalid meeting with the understanding that he had no authority to chair any such shareholder meeting. At the pretend special meeting, this group announced pretend 'voting results' from a 'vote' that did not take place due to the valid adjournment. The following day, SAIF and the Dissenting Investor Group held a pretend meeting to elect a pretend Chairman. Valid SINOVAC shareholders are admonished to ignore these theatrics. The Board, consisting of Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven Borho and Mr. Geoffrey Hsu, retains full authority to run SINOVAC. None of the pretend board's rogue actions are valid or legal. SAIF and the Dissenting Investor Group will be held responsible. At the time of the Special Meeting, the injunction granted by the Eastern Caribbean Supreme Court of Antigua and Barbuda (the 'Antigua High Court') on July 7, 2025 – prohibiting the PIPE shares from voting at the meeting – had not been overturned. While the Eastern Caribbean Court of Appeal temporarily stayed the injunction order, the stay is in place until a hearing is held to determine whether such stay should have been granted. On July 11, 2025, Judge Bakre of the Antigua High Court issued a ruling, which stated that granting a stay would make a 'mockery' of this case. There are ongoing legal proceedings in Antigua to determine the validity of the PIPE shares. The current Board will reconvene the Special Meeting once this issue is resolved by the proper court. During this period, voting is unavailable. All valid shareholders will have their vote counted at the validly reconvened Special Meeting. The current SINOVAC Board remains in place, is governing the Company, and is executing on its stated priorities. These include dividend distributions according to its previously announced policy, in addition to the ongoing payment of the US$55.00 per common share special cash dividend paid to valid shareholders or their brokers beginning on July 7, 2025, working with NASDAQ to resume trading, the appointment of a new auditor, and exploring a future listing on the Stock Exchange of Hong Kong to promote liquidity and maximize value creation. The SINOVAC Board urges all shareholders to rely only on official communications from the rightful Board for accurate information. The Board remains committed to transparency and the rule of law and will provide further updates as developments occur. For ongoing updates and further information, please visit About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Time of India
07-07-2025
- Science
- Time of India
5 most rare snakes in the world that cannot be spotted easily
Discover some of the world's rarest snakes. The St. Lucia Racer, Antiguan racer, and Albany adder face critical endangerment. The short-nosed sea snake was rediscovered in Australia. Bailey's hot-spring snake lives in Tibet. Conservation efforts offer hope. These snakes highlight the need to protect ecosystems. Their survival depends on preserving their unique habitats. It gives an exceptional thrill to learn about the world's most elusive snakes, including those slithering reptiles that are vanishing with the changing conditions of the environment and which only a few humans will ever see. These rare reptiles remind us how the ecosystems need to be taken care of and how much of nature still lies hidden. Snakes survive in remote, specially adapted habitats, and their scarcity highlights how unique they are and how vulnerable they can be. Here are five of these extraordinary creatures of the snake kingdom. St. Lucia racer Considered the rarest snake globally, with fewer than 20 individuals left, the St. Lucia Racer lives on St. Lucia's tiny Maria Major islet in the Caribbean. This non‑venomous colubrid blends into dry scrubland, preying on lizards. Declared extinct in 1936, it was rediscovered in 1973 and remains critically endangered due to invasive mongooses and habitat loss. Antiguan racer It was once limited to the 8-hectare Great Bird Island off Antigua, and the Antiguan racer population was reduced to about 51 by 1995. Since then, it has rebounded to over 1,100 by the removal of invasive species and habitat restoration. Non‑venomous and shy, it lives in coastal woodlands and beaches. Though still critically endangered, this recovery effort offers hope to other rare island snakes. Albany adder A small, venomous viper found only in South Africa's Eastern Cape, the Albany adder went unseen for decades until its rediscovery in 2016. With fewer than 12 recorded sightings, it's critically endangered. It also remains camouflaged mainly among fynbos and dune vegetation, it faces threats from habitat loss and illegal collection. Short‑nosed sea snake This rare marine serpent, also known as the Sahul reef snake, inhabits coral reefs off northwestern Australia, including Ashmore and Hibernia Reefs. It was long thought extinct until a 2021 rediscovery; it's critically endangered due to coral bleaching and ocean changes. Its specialized reef habitat makes it extremely shy and rarely seen. Bailey's hot‑spring snake This high-altitude snake lives only in Tibet, near hot springs on the Tibetan Plateau above 4,300 m. Known from a few sites, it's near-threatened due to its limited distribution. Adapted to volcanic streams, it remains rarely seen by humans. Its spartan habitat makes it one of Asia's most enigmatic snakes.
Business Wire
30-06-2025
- Business
- Business Wire
SINOVAC Board of Directors Urges Shareholders to Vote the WHITE Proxy Card 'AGAINST' the Misguided Proposals to Remove SINOVAC's Current Board
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today sent a letter to shareholders ahead of the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). The full text of the letter follows: Dear SINOVAC Shareholder, It is time to act. Your vote at the upcoming Special Meeting of Shareholders will shape SINOVAC's future. SAIF has called this Special Meeting to reconstitute a remnant of the Former Board that the UK Privy Council deemed to be 'Imposters' in its final, non-appealable January 2025 ruling. Proposing this slate (the 'Reconstituted Imposter Former Board Slate') is the latest scheme by Advantech/Prime Success ('Advantech/Prime'), Vivo Capital (together, the 'Dissenting Investor Group'), and other members of the Former Management Buyout Consortium to seize control of SINOVAC at the expense of common shareholders. While your current SINOVAC Board has been delivering on its promises to restore fairness and deliver value to all SINOVAC shareholders, the Dissenting Investor Group has been continuing its attempt to derail our progress through misleading rhetoric, baseless claims and frivolous legal actions. Their self-serving strategies pose a direct threat to the value of your investment and the future of SINOVAC. The facts speak for themselves: COMMITMENT TO DECLARING DIVIDENDS Since it was installed by the Privy Council ruling, and in accordance with Antiguan law, in just four months, the current SINOVAC Board has: Declared a US$55.00 per common share special cash dividend due to be paid on July 7, 2025. Announced plans for an additional US$11.00 per common share cash dividend, contingent on the cancellation of the unauthorized PIPE shares acquired by Advantech/Prime and Vivo Capital. Decided to declare a second special cash dividend of US$19.00 per common share, with the potential of an additional US$3.73 per common share if the PIPE shares are cancelled. Adopted a policy to issue regular dividends out of surplus cash, with potential future distributions of US$20.00 - US$50.00 per common share. IN CONTRAST, the Imposter Former Board failed to declare any dividends to common shareholders during the seven years it presided over SINOVAC, while draining cash from subsidiaries for itself to the exclusion of common shareholders. Today, the Imposter Former Board blames litigation during 2018-2024 as the reason it couldn't pay dividends, but ironically, the litigation it tried to use as an excuse did not prevent the Imposter Former Board's cronies from pocketing more than US$2 billion in dividends from our operating subsidiary. In a statement from the Company's 2023 20-F filed in April 2024, the Board stated it did not 'have any present plan to pay any cash dividends on Sinovac Antigua's shares in the foreseeable future.' The Imposter Former Board did not say the non-dividend policy was because of litigation. However, the onslaught of baseless, multi-jurisdictional lawfare by the same bad actors did not prevent the current SINOVAC Board from declaring the US$55.00 per common share cash dividend. Their lawsuits, intended to interfere with the dividend payout to all valid shareholders, have been defeated in New York and Hong Kong. The Reconstituted Imposter Former Board Slate, while paying lip service to endorsing our US$55.00 per common share cash dividend, haven't yet supported the additional dividends we've declared or our new dividend policy. Their sudden interest in dividends is nothing more than a hollow promise. We believe they would seek to privatize the Company again at below market prices and deprive shareholders of their rightful cash distributions. Shareholders should be asking the Reconstituted Imposter Former Board Slate this question: will you publicly support the current SINOVAC Board's plans for additional cash dividends and the dividend policy it recently adopted? RESUMPTION OF GOOD RELATIONS WITH NASDAQ AND REGULATORS The current SINOVAC Board has done significant work to unwind the seven years of compliance shortcomings that occurred under the Imposter Former Board, which directly led to the NASDAQ trading halt. This work includes: Engaging senior NASDAQ officials to regain compliance, resume trading and support the US$55.00 per share special cash dividend. Launching a formal exploration of a future listing on the Stock Exchange of Hong Kong to promote liquidity, mitigate geopolitical risk and maximize shareholder value. Tasking its Audit Committee with conducting a process to evaluate and select a new independent registered public accounting firm and end the revolving door of auditing firms under the Imposter Former Board. IN CONTRAST, the Reconstituted Imposter Former Board Slate is responsible for the very issues they now claim they'll resolve. Their unlawful actions triggered the 2019 NASDAQ trading halt and forced the resignation of Grant Thornton, SINOVAC's former auditor, due to sham transactions. PROTECTING VALID SINOVAC SHAREHOLDERS AND PAYING DIVIDENDS IN THE FACE OF CONTINUOUS LAWFARE WAGED BY ADVANTECH/PRIME AND VIVO CAPITAL The current SINOVAC Board is committed to fighting the self-serving, continuous and wasteful lawfare from the Dissenting Investor Group, which includes filing suits in New York and Hong Kong, and seeking injunctions designed to interfere with the payment of the US$55.00 special cash dividend to all common shareholders. In response to this self-serving lawfare strategy, the current SINOVAC Board has: Vigorously defended our position and prevailed against Advantech/Prime in New York and Hong Kong. Committed to fighting to protect valid shareholders and redistribute funds that were improperly allocated to the invalid PIPE shareholders. IN CONTRAST, the Dissenting Investor Group continues to talk out of both sides of their mouth – pretending they are in favor of dividend payments while filing intentionally vague lawsuits intended to deprive common shareholders of rightful dividend payments. The Reconstituted Imposter Former Board Slate would allow these actions to continue unchecked. In addition to dividends, the current SINOVAC Board is taking the necessary steps to correct the injustices of the past, position the Company for a brighter future and enhance governance by: Accelerating the resumption of trading on NASDAQ and exploring future listings on other exchanges. Planning an annual meeting of shareholders in the second quarter of 2026 to nominate a full slate of highly-qualified and independent directors. Executing a global growth strategy to expand SINOVAC's business in China and globally, leveraging our position as a leading provider of vaccine products. IN CONTRAST, during the seven years it presided over the Company, the Imposter Former Board demonstrated a pattern of self-dealing that allowed Advantech/Prime, Vivo Capital and their cronies to loot billions of dollars from SINOVAC while common SINOVAC shareholders received nothing. During that time, the Imposter Former Board approved an invalid PIPE transaction, which is in the process of being unwound, gifted Advantech/Prime and Vivo Capital shares of SINOVAC's operating subsidiary, granted shares to select minority shareholders, doled out excessive bonuses to the SINOVAC management team, and enabled non-arms length investments by SINOVAC of nearly US$100 million in Vivo Capital Funds. Shareholders should ask themselves: do you think the Imposter Former Board Slate would really have all SINOVAC shareholders' best interests in mind? We doubt it. YOUR VOTE IS IMPORTANT The Special Meeting of Shareholders (the 'Special Meeting') will be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). Your vote determines SINOVAC's future, receipt of your dividend payments and the long-term value of your investment. The facts are clear, and so is the choice. We urge you to vote on the WHITE proxy card: ' AGAINST ' Proposal 1 to remove the current SINOVAC Board. ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! THANK YOU We thank you for your continued confidence and support as we work to protect your investment and the future of SINOVAC. If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ For more information, visit Sincerely, The SINOVAC Board of Directors About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
